中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
上海药物研究所 [95]
西北高原生物研究所 [40]
昆明植物研究所 [12]
合肥物质科学研究院 [7]
武汉植物园 [6]
过程工程研究所 [5]
更多
采集方式
OAI收割 [207]
iSwitch采集 [7]
内容类型
期刊论文 [209]
会议论文 [3]
学位论文 [2]
发表日期
2023 [10]
2022 [12]
2021 [11]
2020 [7]
2019 [16]
2018 [31]
更多
学科主题
Pharmacolo... [4]
Biochemist... [3]
Toxicology [2]
Biochemist... [1]
Biochemist... [1]
Cell Biolo... [1]
更多
筛选
浏览/检索结果:
共214条,第1-10条
帮助
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
提交时间升序
提交时间降序
发表日期升序
发表日期降序
题名升序
题名降序
作者升序
作者降序
Low-Dose Chemotherapy Preferentially Shapes the Ileal Microbiome and Augments the Response to Immune Checkpoint Blockade by Activating AIM2 Inflammasome in Ileal Epithelial Cells
期刊论文
OAI收割
ADVANCED SCIENCE, 2024, 页码: 17
作者:
Pu, Congying
;
Li, Yize
;
Fu, Yixian
;
Yan, Yiyang
;
Tao, Siyao
  |  
收藏
  |  
浏览/下载:21/0
  |  
提交时间:2024/02/27
AIM2 inflammasome
chemotherapy
gut microbiome
ileal epithelial cells
immune checkpoint blockade
lactobacillus
segmented filamentous bacterium
LINC00955 suppresses colorectal cancer growth by acting as a molecular scaffold of TRIM25 and Sp1 to Inhibit DNMT3B-mediated methylation of the PHIP promoter
期刊论文
OAI收割
BMC CANCER, 2023, 卷号: 23, 期号: 1, 页码: 20
作者:
Ren, Ganglin
;
Li, Hongyan
;
Hong, Dan
;
Hu, Fangyu
;
Jin, Rongjia
  |  
收藏
  |  
浏览/下载:6/0
  |  
提交时间:2023/12/08
LINC00955
Colorectal cancer
Cell cycle
CDK2
PHIP
Sp1
Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of ROR & gamma; antagonists
期刊论文
OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 卷号: 257, 页码: 15
作者:
Mei, Lianghe
;
Xu, Lansong
;
Wu, Sanan
;
Wang, Yafang
;
Xu, Chao
  |  
收藏
  |  
浏览/下载:39/0
  |  
提交时间:2023/10/17
Betulinic acid
ROR & gamma
Target identification
Rationale structure optimization
Anti-tumor effects
antagonists
Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment
期刊论文
OAI收割
MOLECULAR DIVERSITY, 2023, 页码: 20
作者:
Ding, Mengyuan
;
Shen, Qianqian
;
Lu, Wei
;
Zhu, Shulei
  |  
收藏
  |  
浏览/下载:62/0
  |  
提交时间:2023/10/17
EGFR
HER2
NAMPT
Resistance
Selectivity
Molecular docking
Discovery of HyT-Based Degraders of CDK9-Cyclin T1 Complex
期刊论文
OAI收割
CHEMISTRY & BIODIVERSITY, 2023, 页码: 10
作者:
Lin, Rongkun
;
Yang, Jie
;
Liu, Ting
;
Wang, Mingyu
;
Ke, Chongrong
  |  
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2023/10/17
CDK9
cyclin T1
degrader
hydrophobic tag
protein degradation
Discovery of new small molecule inhibitors of the BPTF bromodomain
期刊论文
OAI收割
BIOORGANIC CHEMISTRY, 2023, 卷号: 134, 页码: 106453
作者:
Liang, Xiaochen
;
Cao, Yu
;
Duan, Zhe
;
Wang, Mingchen
;
Zhang, Naixia
  |  
收藏
  |  
浏览/下载:2/0
  |  
提交时间:2024/03/27
BPTF bromodomain
BPTF inhibitors
HTRF
c-Myc
Discovery of LL-K8-22: A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 卷号: 66, 期号: 7, 页码: 4932-4951
作者:
Wang, Mingyu
;
Lin, Rongkun
;
Li, Jiacheng
;
Suo, Yuying
;
Gao, Jing
  |  
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2023/10/17
Multi-omics profiling of PC-3 cells reveals bufadienolides-induced lipid metabolic remodeling by regulating long-chain lipids synthesis and hydrolysis
期刊论文
OAI收割
METABOLOMICS, 2023, 卷号: 19, 期号: 2, 页码: 13
作者:
Zhang, Rong
;
Zhang, Zijia
;
Wu, Wenyong
;
Shi, Jingying
;
Berk, Entezar
  |  
收藏
  |  
浏览/下载:19/0
  |  
提交时间:2023/04/10
Bufadienolides
Prostate cancer
Lipidomics
Transcriptomics
ELOVL6
PLD1
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 页码: 18
作者:
Tang, Hairong
;
Yu, Aisong
;
Xing, Li
;
Chen, Xiaoyu
;
Ding, Huaqian
  |  
收藏
  |  
浏览/下载:16/0
  |  
提交时间:2023/04/10
Design, synthesis and biological evaluation of KRASG12C-PROTACs
期刊论文
OAI收割
BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 卷号: 78, 页码: 14
作者:
Zhang, Xiaoyi
;
Zhao, Tong
;
Sun, Minghao
;
Li, Pei
;
Lai, Mengzhen
  |  
收藏
  |  
浏览/下载:13/0
  |  
提交时间:2023/04/10
KRASG12C
PROTAC
Covalent inhibitors
Structure-activity relationships (SARs)
Anticancer